N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
Arne Zibat, Xiaoxiao Zhang, Antje Dickmanns, Kim M Stegmann, Adrian Dobbelstein, Halima Alachram, Rebecca Soliwoda, Gabriela Salinas, Uwe Groß, Dirk Görlich, Maik Kschischo, Bernd Wollnik, Matthias Dobbelstein
iScience, doi:10.1016/j.isci.2023.107786
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
J o u r n a l P r e -p r o o f additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. • This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS Vero E6 cells (Vero C1008) were obtained from the German Primate Research Center Göttingen. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM with GlutaMAX TM , Gibco) supplemented with 10% fetal bovine serum (FBS; Merck), 50 units/mL penicillin, 50 μg/mL streptomycin (Gibco), 2 µg/mL tetracycline (Sigma) and 10 µg/mL ciprofloxacin (Bayer) at 37°C in a humidified atmosphere with 5% CO2. Vero E6 cells were authenticated in 2021 by means of Cytochrome C Subunit I (COI) DNA Barcoding by the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). Furthermore, the cells were routinely tested to ensure they were negative for mycoplasma contamination, using the MycoAlert Assay Control Set (Lonza).
J o u r n a l P r e -p r o o f
References
Agostini, Pruijssers, Chappell, Gribble, Lu et al., Small-Molecule Antiviral β-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance, J Virol,
doi:10.1128/jvi.01348-19Alteri, Fox, Scutari, Burastero, Volpi et al., A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drugnaïve patients, Commun Biol,
doi:1376.10.1038/s42003-022-04322-8Andrews, FastQC -a quality control tool for high throughput sequencing data
Bajema, Berry, Streja, Rajeevan, Li et al., Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes, Ann Intern Med,
doi:10.7326/m22-3565Bernal, Gomes Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med,
doi:10.1056/NEJMoa2116044Butt, Yan, Molnupiravir Use and 30-Day Hospitalizations or Death in Previously Uninfected Non-hospitalized Highrisk Population with COVID-19, J Infect Dis,
doi:10.1093/infdis/jiad195Chan, Law, Ho, Chan, Ma et al., Genomic characteristics and viral load dynamics of a SARS-CoV-2 Omicron BA.2.2 variant from a hospitalized patient treated with molnupiravir, Infect Genet Evol,
doi:105376.10.1016/j.meegid.2022.105376Chatterjee, Bhattacharya, Dhama, Lee, Chakraborty, Molnupiravir's mechanism of action drives "error catastrophe" in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus, Mol Ther Nucleic Acids,
doi:10.1016/j.omtn.2023.06.006Chen, Turcinovic, Feng, Kenney, Chin et al., Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus,
doi:10.1016/j.isci.2023.106634Chiliveri, Louis, Ghirlando, Bax, Transient lipid-bound states of spike protein heptad repeats provide insights into SARS-CoV-2 membrane fusion, Sci Adv,
doi:2226.10.1126/sciadv.abk2226Cingolani, Platts, Wang Le, Coon, Nguyen et al., A program for annotating and predicting the effects of single nucleotide polymorphisms, Fly,
doi:10.4161/fly.19695Coutard, Valle, De Lamballerie, Canard, Seidah et al., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade, Antiviral Res,
doi:104742.10.1016/j.antiviral.2020.104742Cox, Wolf, Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat Microbiol,
doi:10.1038/s41564-020-00835-2Crotty, Maag, Arnold, Zhong, Lau et al., The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen, Nature Medicine,
doi:10.1038/82191Donovan-Banfield, Penrice-Randal, Goldswain, Rzeszutek, Pilgrim et al., Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial, Nat Commun,
doi:7284.10.1038/s41467-022-34839-9Emeny, Morgan, Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production, J Gen Virol,
doi:10.1099/0022-1317-43-1-247Fillâtre, Dufour, Behillil, Vatan, Reusse et al., A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study, Clin Microbiol Infect,
doi:10.1016/j.cmi.2021.09.035Fischer, Eron, Jr, Holman, Cohen et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med,
doi:7430.10.1126/scitranslmed.abl7430Garrison, Kronenberg, Dawson, Pedersen, Prins, A spectrum of free software tools for processing the VCF variant call format: vcflib, biovcf, cyvcf2, hts-nim and slivar, PLoS Comput Biol,
doi:1009123.10.1371/journal.pcbi.1009123Grubaugh, Gangavarapu, Quick, Matteson, De et al., An ampliconbased sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar, Genome Biol,
doi:10.1186/s13059-018-1618-7Güttler, Aksu, Dickmanns, Stegmann, Gregor et al., Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies, The EMBO Journal
Hoffmann, Krüger, Schulz, Cossmann, Rocha et al., The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic,
doi:10.1016/j.cell.2021.12.032Ivanov, Taldaev, Lisitsa, Ponomarenko, Archakov, Prediction of Monomeric and Dimeric Structures of CYP102A1 Using AlphaFold2 and AlphaFold Multimer and Assessment of Point Mutation Effect on the Efficiency of Intra-and Interprotein Electron Transfer, Molecules
Jangra, Ye, Rathnasinghe, Stadlbauer, Krammer et al., SARS-CoV-2 spike E484K mutation reduces antibody neutralisation, Lancet Microbe,
doi:10.1016/s2666-5247(21)00068-9Jena, Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19, Phys Chem Chem Phys,
doi:10.1039/d0cp05297cJohnson, Xie, Bailey, Kalveram, Lokugamage et al., Loss of furin cleavage site J o u r n a l P r e -p r o o f attenuates SARS-CoV-2 pathogenesis,
doi:10.1038/s41586-021-03237-4Kabinger, Stiller, Schmitzova, Dienemann, Kokic et al., Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat Struct Mol Biol,
doi:10.1038/s41594-021-00651-0Kobayashi, Mori, Ahmed, Hirao, Kato et al., Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir, J Infect Dis,
doi:10.1093/infdis/jiac477Koenig, Das, Liu, Kümmerer, Gohr et al., Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape, Science,
doi:10.1126/science.abe6230Kärber, Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie,
doi:10.1007/BF01863914Mahase, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, Bmj,
doi:2713.10.1136/bmj.n2713Mahase, Covid-19: UK becomes first country to authorise antiviral molnupiravir, BMJ,
doi:10.1136/bmj.n2697Malin, Weibel, Gruell, Kreuzberger, Stegemann et al., Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis, J Antimicrob Chemother,
doi:1586-1598.10.1093/jac/dkad132Mcgaughey, Gagné, Rappé, pi-Stacking interactions. Alive and well in proteins, The Journal of biological chemistry,
doi:10.1074/jbc.273.25.15458Miranda, Mckinzie, Dobrovolsky, Revollo, Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing, Environ Mol Mutagen,
doi:10.1002/em.22510Molina-Mora, Cordero-Laurent, Godínez, Calderón-Osorno, Brenes et al., SARS-CoV-2 genomic surveillance in Costa Rica: Evidence of a divergent population and an increased detection of a spike T1117I mutation, Infect Genet Evol,
doi:104872.10.1016/j.meegid.2021.104872Motozono, Toyoda, Zahradnik, Saito, Nasser et al., SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity, Cell Host Microbe,
doi:1111.10.1016/j.chom.2021.06.006Najjar-Debbiny, Gronich, Weber, Khoury, Amar et al., Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis, Clinical Infectious Diseases,
doi:10.1093/cid/ciac781Ogando, Dalebout, Zevenhoven-Dobbe, Limpens, Van Der Meer et al., SARScoronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology, J Gen Virol,
doi:10.1099/jgv.0.001453Ou, Zhu, trackViewer: a Bioconductor package for interactive and integrative visualization of multi-omics data, Nat Methods,
doi:10.1038/s41592-019-0430-yPak, Markhieva, Novikova, Petrov, Vorobyev et al., Using AlphaFold to predict the impact of single mutations on protein stability and function, bioRxiv,
doi:460937.10.1101/2021.09.19.460937Peacock, Goldhill, Zhou, Baillon, Frise et al., The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets, Nat Microbiol,
doi:10.1038/s41564-021-00908-wReynard, Nguyen, Alazard-Dany, Barateau, Cimarelli et al., Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication, Viruses,
doi:10.3390/v7122934Rosenke, Okumura, Lewis, Feldmann, Meade-White et al., Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model, JCI Insight,
doi:10.1172/jci.insight.160108Sanderson, Hisner, Donovan-Banfield, Hartman, Løchen et al., Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases. medRxiv,
doi:23284998.10.1101/2023.01.26.23284998Sen, Anishchenko, Bordin, Sillitoe, Velankar et al., Characterizing and explaining the impact of disease-associated mutations in proteins without known structures or structural homologs, Briefings in bioinformatics,
doi:10.1093/bib/bbac187Service, A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm,
doi:10.1126/science.acx9591Sheahan, Sims, Zhou, Graham, Pruijssers et al., An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med,
doi:10.1126/scitranslmed.abb5883Stegmann, Dickmanns, Gerber, Nikolova, Klemke et al., The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models, Virus Res,
doi:198469.10.1016/j.virusres.2021.198469Stegmann, Dickmanns, Heinen, Blaurock, Karrasch et al., Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication,
doi:104293.10.1016/j.isci.2022.104293Sztain, Ahn, Bogetti, Casalino, Goldsmith et al., A glycan gate controls opening of the SARS-CoV-2 spike protein, Nature Chemistry,
doi:10.1038/s41557-021-00758-3Toots, Yoon, Cox, Hart, Sticher et al., Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia, Sci Transl Med,
doi:10.1126/scitranslmed.aax5866Toots, Yoon, Hart, Natchus, Painter et al., Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model, Transl Res,
doi:10.1016/j.trsl.2019.12.002Wahl, Gralinski, Johnson, Yao, Kovarova et al., SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature,
doi:10.1038/s41586-021-03312-wWaters, Warren, Hughes, Lewis, Zhang, Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir, Environ Mol Mutagen,
doi:10.1002/em.22471Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet,
doi:10.1016/s0140-6736(22)01586-0Xia, Liu, Wang, Xu, Lan et al., Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion, Cell Res,
doi:10.1038/s41422-020-0305-xXu, Wang, Liu, Zhang, Han et al., Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM, Sci Adv,
doi:10.1126/sciadv.abe5575Yi, Kim, Bleazard, Kim, Youk et al., Mutational spectrum of SARS-CoV-2 during the global pandemic, Experimental & Molecular Medicine,
doi:10.1038/s12276-021-00658-zYip, Low, Chow, Lal, Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity, Viruses,
doi:10.3390/v14061345Zhang, Xiang, Huo, Zhou, Jiang et al., Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy, Signal Transduction and Targeted Therapy,
doi:233.10.1038/s41392-021-00653-wZhao, Abbasi, Illingworth, Mutational load causes stochastic evolutionary outcomes in acute RNA viral infection, Virus Evolution,
doi:008.10.1093/ve/vez008Zhou, Xie, Tang, Pu, Zhu et al., Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies, Signal Transduction and Targeted Therapy,
doi:317.10.1038/s41392-021-00733-x{ 'indexed': {'date-parts': [[2023, 8, 31]], 'date-time': '2023-08-31T13:40:40Z', 'timestamp': 1693489240326},
'reference-count': 0,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2023, 8, 1]],
'date-time': '2023-08-01T00:00:00Z',
'timestamp': 1690848000000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2023, 8, 29]],
'date-time': '2023-08-29T00:00:00Z',
'timestamp': 1693267200000},
'content-version': 'vor',
'delay-in-days': 28,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'content-domain': { 'domain': ['cell.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2023, 8]]},
'DOI': '10.1016/j.isci.2023.107786',
'type': 'journal-article',
'created': {'date-parts': [[2023, 8, 30]], 'date-time': '2023-08-30T16:07:59Z', 'timestamp': 1693411679000},
'page': '107786',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and '
'escape from a neutralizing nanobody',
'prefix': '10.1016',
'author': [ {'given': 'Arne', 'family': 'Zibat', 'sequence': 'first', 'affiliation': []},
{'given': 'Xiaoxiao', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Antje', 'family': 'Dickmanns', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kim M.', 'family': 'Stegmann', 'sequence': 'additional', 'affiliation': []},
{'given': 'Adrian', 'family': 'Dobbelstein', 'sequence': 'additional', 'affiliation': []},
{'given': 'Halima', 'family': 'Alachram', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rebecca', 'family': 'Soliwoda', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gabriela', 'family': 'Salinas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Uwe', 'family': 'Groß', 'sequence': 'additional', 'affiliation': []},
{'given': 'Dirk', 'family': 'Görlich', 'sequence': 'additional', 'affiliation': []},
{'given': 'Maik', 'family': 'Kschischo', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bernd', 'family': 'Wollnik', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5052-3967',
'authenticated-orcid': False,
'given': 'Matthias',
'family': 'Dobbelstein',
'sequence': 'additional',
'affiliation': []}],
'member': '78',
'container-title': 'iScience',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2589004223018631?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S2589004223018631?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2023, 8, 30]],
'date-time': '2023-08-30T16:08:00Z',
'timestamp': 1693411680000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2589004223018631'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 8]]},
'references-count': 0,
'alternative-id': ['S2589004223018631'],
'URL': 'http://dx.doi.org/10.1016/j.isci.2023.107786',
'relation': {},
'ISSN': ['2589-0042'],
'subject': ['Multidisciplinary'],
'container-title-short': 'iScience',
'published': {'date-parts': [[2023, 8]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 '
'mutagenesis and escape from a neutralizing nanobody',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'iScience', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.isci.2023.107786',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{'value': '© 2023 The Author(s).', 'name': 'copyright', 'label': 'Copyright'}],
'article-number': '107786'}
